Brian Hess

2.1k total citations · 1 hit paper
53 papers, 597 citations indexed

About

Brian Hess is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Brian Hess has authored 53 papers receiving a total of 597 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 26 papers in Pathology and Forensic Medicine and 15 papers in Genetics. Recurrent topics in Brian Hess's work include Lymphoma Diagnosis and Treatment (26 papers), CAR-T cell therapy research (24 papers) and Chronic Lymphocytic Leukemia Research (15 papers). Brian Hess is often cited by papers focused on Lymphoma Diagnosis and Treatment (26 papers), CAR-T cell therapy research (24 papers) and Chronic Lymphocytic Leukemia Research (15 papers). Brian Hess collaborates with scholars based in United States, United Kingdom and Italy. Brian Hess's co-authors include Brad S. Kahl, Melhem Solh, Carmelo Carlo‐Stella, Pier Luigi Zinzani, Juan Pablo Alderuccio, Kirit M. Ardeshna, Weiyun Z. Ai, John Radford, Paolo F. Caimi and Anastasios Stathis and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Brian Hess

48 papers receiving 590 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

2021 264 citations Paolo F. Caimi, Weiyun Z. Ai et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brian Hess United States	11	452	354	122	115	96	53	597
Aleš Obr Czechia	8	384 0.8×	366 1.0×	74 0.6×	80 0.7×	125 1.3×	21	483
David Lewis United Kingdom	12	388 0.9×	354 1.0×	120 1.0×	103 0.9×	138 1.4×	39	546
Huang Huang Canada	8	343 0.8×	245 0.7×	93 0.8×	126 1.1×	69 0.7×	14	413
Gloria Iacoboni Spain	16	588 1.3×	294 0.8×	111 0.9×	92 0.8×	116 1.2×	65	730
Pratyush Giri Australia	9	337 0.7×	253 0.7×	142 1.2×	140 1.2×	93 1.0×	29	451
Dorothea Wessiepe Germany	5	497 1.1×	126 0.4×	198 1.6×	160 1.4×	48 0.5×	5	669
Nicole Adrian Germany	8	323 0.7×	192 0.5×	131 1.1×	111 1.0×	66 0.7×	10	428
Marie-Elisabeth Goebeler Germany	6	324 0.7×	197 0.6×	110 0.9×	100 0.9×	67 0.7×	7	392
Lori A. Leslie United States	11	252 0.6×	168 0.5×	84 0.7×	23 0.2×	125 1.3×	73	412
Pim Mutsaers Netherlands	8	270 0.6×	185 0.5×	59 0.5×	18 0.2×	41 0.4×	30	371

Countries citing papers authored by Brian Hess

Since Specialization

Citations

This map shows the geographic impact of Brian Hess's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Hess with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Hess more than expected).

Fields of papers citing papers by Brian Hess

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Hess. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Hess. The network helps show where Brian Hess may publish in the future.

Co-authorship network of co-authors of Brian Hess

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Hess. A scholar is included among the top collaborators of Brian Hess based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Hess. Brian Hess is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Davis, James A., et al.. (2024). Practical Implications of Multi-Institution Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity (ICANS) Rates in Lymphoma Targeted Bispecific Antibodies (BsAb). Blood. 144(Supplement 1). 2350–2350. 2 indexed citations

Davis, James A., et al.. (2024). “Fast but not so furious”: A condensed step‐up dosing schedule of teclistamab for relapsed/refractory multiple myeloma. SHILAP Revista de lepidopterología. 5(4). 793–797. 1 indexed citations

Balkema‐Buschmann, Anne, et al.. (2024). Distribution and suitability of pulmonary surfactants as a vehicle for topically applied antibodies in healthy and SARS-CoV-2 infected rodent lungs. European Journal of Pharmaceutical Sciences. 196. 106744–106744.

Sawalha, Yazeed, Brian Hess, Audrey M. Sigmund, et al.. (2023). Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial. Blood. 142(Supplement 1). 6226–6226.

Hamadani, Mehdi, Alexander I. Spira, Xiaolei Zhou, et al.. (2023). Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial. Blood Advances. 8(1). 93–98. 5 indexed citations

Hess, Brian, Nasheed Hossain, Volkan Beylergil, et al.. (2023). SWOG 2114: A RANDOMIZED PHASE II TRIAL OF CONSOLIDATION THERAPY FOLLOWING CD19 CAR T‐CELL TREATMENT FOR RELAPSED/REFRACTORY LARGE B‐CELL OR GRADE IIIB FOLLICULAR LYMPHOMA. Hematological Oncology. 41(S2). 839–840. 3 indexed citations

Soong, David S., Catherine Thiéblemont, John Karavitis, et al.. (2023). Evaluation of ctDNA in a phase I/II trial in relapsed or refractory large B‐cell lymphoma of epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T‐cell–engaging antibody. Hematological Oncology. 41(S2). 326–328. 2 indexed citations

Schandl, Cynthia A., Georges J. Nahhas, Dongjun Chung, et al.. (2023). Novel high–risk acute myeloid leukemia subgroup with ERG amplification and Biallelic loss of TP53. Cancer Genetics. 272-273. 23–28. 2 indexed citations

Davis, James A., et al.. (2023). Early versus standard management of chimeric antigen receptor therapy toxicities and management's impact on safety and efficacy. Journal of Oncology Pharmacy Practice. 30(1). 151–158. 2 indexed citations

10.

Caimi, Paolo F., Weiyun Z. Ai, Juan Pablo Alderuccio, et al.. (2023). Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study. Haematologica. 109(4). 1184–1193. 23 indexed citations

11.

Alderuccio, Juan Pablo, Weiyun Z. Ai, John Radford, et al.. (2022). Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study. Blood Advances. 6(16). 4736–4739. 1 indexed citations

12.

Davis, James A., et al.. (2022). Fever Characteristics and Impact on Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy. Clinical Lymphoma Myeloma & Leukemia. 23(1). e14–e18. 2 indexed citations

13.

Hess, Brian, et al.. (2021). Clinical utility of chromosomal microarray in establishing clonality and high risk features in patients with Richter transformation. Cancer Genetics. 260-261. 18–22. 4 indexed citations

14.

Caimi, Paolo F., Weiyun Z. Ai, Juan Pablo Alderuccio, et al.. (2021). Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. The Lancet Oncology. 22(6). 790–800. 264 indexed citations breakdown →

15.

Hess, Brian, William Townsend, Weiyun Z. Ai, et al.. (2021). Efficacy and Safety Exposure–Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma. The AAPS Journal. 24(1). 11–11. 8 indexed citations

16.

Herrera, Alex F., Carmelo Carlo‐Stella, Graham P. Collins, et al.. (2020). Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood. 136(Supplement 1). 21–23. 14 indexed citations

17.

Ribrag, Vincent, Seung‐Tae Lee, David A. Rizzieri, et al.. (2020). A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 21(5). 309–317.e3. 19 indexed citations

18.

Neppalli, Amarendra Kumar, et al.. (2019). Large Granular Lymphocytosis after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study. Biology of Blood and Marrow Transplantation. 25(3). S330–S330. 2 indexed citations

19.

Hess, Brian, Feng Gao, John F. DiPersio, et al.. (2015). Use of Post-Transplant Cyclophosphamide (PTCy) with Mycophenolate Mofetil and Tacrolimus in HLA Matched Allogeneic Hematopoietic Cell Transplant Is Safe and Associated with Acceptable Transplant Outcomes. Blood. 126(23). 1950–1950. 6 indexed citations

20.

Hess, Brian, Stephen Olejnik, & Carl J. Huberty. (2001). The Efficacy of Two Improvement-Over-Chance Effect Sizes for Two-Group Univariate Comparisons Under Variance Heterogeneity and Nonnormality. Educational and Psychological Measurement. 61(6). 909–909. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact